Navigation Links
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"We are thrilled to have reached the halfway point for enrollment in our GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "Once complete, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved patient outcomes. We continue our commitment to ensuring that the VerifyNow System is shown to be an integral tool in optimizing the use of antiplatelet therapy."

About GRAVITAS

The concept of variability in response to antiplatelet therapy has been well established. Also being demonstrated with increased frequency is the question of whether poor response to antiplatelet therapy, based on a laboratory test, leads to poor patient outcomes. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antip
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
4. Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare Reform
5. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
6. Spherix Announces Positive Phase 2 Study Results
7. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
8. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
9. CoAxia, Inc. Announces $21.5M Series D Financing
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
(Date:12/16/2009)... December 16 Biovista Inc.,today announced that ... Award,in Healthcare, at the 2009 New England Venture ... award, which recognizes cutting edge private companies,driving the ... competed with,over 50 other privately held companies that ... Life Sciences and Clean-tech sectors. , ...
(Date:12/16/2009)... ANN ARBOR, Mich., Dec. 16 GlaxoSmithKline ... NanoBio Corporation today announced an exclusive licensing agreement ... over-the-counter (OTC) use of NB-001, a novel, patented ... of cold sores. Developed by NanoBio, NB-001 provides ... cold sores, herpes labialis . ,, ...
Breaking Medicine Technology:CareCentrix Receives URAC Health Utilization Management Accreditation 2Biovista Inc. Named Top Innovator in Life Sciences 2GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 210 students receive scholarships for outstanding work in public health systems research 50092 1Cells use import machinery to export their goods as well 9010 1Cells use import machinery to export their goods as well 9010 2Cells use import machinery to export their goods as well 9010 3DuPont Adds Cotton to India Seed Product Lineup 12789 1DuPont Adds Cotton to India Seed Product Lineup 12789 2DuPont Adds Cotton to India Seed Product Lineup 12789 3DuPont Adds Cotton to India Seed Product Lineup 12789 4
... Panel at American Venous Forum Presents Clinical, ... Than Laser, SAN JOSE, Calif., Feb. 23 ... a worldwide leader in medical devices,for the minimally ... clinical performance data for the VNUS ClosureFAST(TM),catheter at ...
... WILMINGTON, Del., Feb. 21 DuPont (NYSE: ... Agricultural,Research Service (ARS) are teaming up to find new ... even in low concentrations, can cause severe illness., ... Meat,Animal Research Center (USMARC) at Clay Center, Neb., and ...
Other Medicine Technology:Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective 2Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective 3Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective 4DuPont and USDA ARS to Collaborate on New E. coli Test in Beef 2
(Date:12/16/2009)... Shoppers like knowing if their salad ... But grocers have found it burdensome to implement ... requiring them to provide the information at point ... easyCOOLnow.com for easily making grocery and produce ... that require retailers of unprocessed fruits, vegetables and ...
(Date:12/16/2009)... SPRINGFIELD, Mass., Dec. 16 MassMutual,s Retirement ... new RetireSmart(SM) participant engagement platform in Q2 2010. ... of enrollment, transition and investment change materials in ... the option to choose from a menu of ... to their own participant population. The new RetireSmart ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
(Date:12/16/2009)... honored to announce that Chris Wepfer and Jackie Kirby have ... Healthcare Traveler magazine’s 2009 Recruiters of the Year Showcase. This ... honors and the first for Jackie. , ... ... national healthcare staffing agency, is honored to announce that Chris ...
(Date:12/16/2009)... International, Inc. (OTC Bulletin Board: MZEI) ... Board of Medizone New Zealand Ltd., a joint ... 50% interest, agreed on December 14, 2009 to ... International all global marketing rights of the company,s ... Marshall said, "Time has eroded the relevance of ...
Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2
... cardiac arrest have typically focused on pre-hospital factors -- ... quicker EMS response. But new research from the University ... where patients are cared for after being resuscitated plays ... these incidents, which takes the lives of more than ...
... Jan. 9 Robert I. Miller, a 25-year ... the Healthcare Industry Group within Siemens IT Solutions ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )In this role, Miller ... the organization,s business plan, including overall go-to-market activities, ...
... Card and Debit Card for Health-related ExpensesPITTSBURGH, Jan. 9 ... with a Flexible Spending Account (FSA) with its new ... is unique to Western Pennsylvania - serves as both a ... for out-of-pocket health care expenses.The My Flex Advantage ...
... oxide laughing gas may be enhanced by ... UCL (University College London). The study,s findings that ... that dental patients may benefit from being coached to ... is commonly used by dentists to sedate their patients ...
... More than 1,800 in Florida Alone ST. PETERSBURG, Fla., ... franchise, announced today the launch of its low-cost, home-based ... consumers containing their comprehensive medical history. eMed-ID is ... medical history on an easy-to-carry or wearable USB device. ...
... Allegheny Financial Group is pleased to announce that James ... magazine as one of the "150 Best Financial Advisors ... Mr. Hohman is one of only six advisors from Pennsylvania ... from Pittsburgh. , , Candidates were selected to ...
Other Medicine News:Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 2Health News:Penn study: Chances of surviving cardiac arrest depend on where patients are treated 3Health News:Miller Joins Siemens IT Solutions and Services as V.P. of Healthcare Industry Group 2Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 2Health News:UPMC Health Plan Introduces `MyFlex Advantage' Card 3Health News:People are more suggestible under laughing gas 2Health News:People are more suggestible under laughing gas 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: